The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Colorectal Disease"
DOI: 10.1007/s00384-021-03855-4
Abstract: Secondary loss of response (LOR) to infliximab (IFX) commonly occurs. One cause is the development of anti-drug antibodies (ADAs). Evidence regarding the optimal management of ADAs is lacking. We aim to identify the best practice… read more here.
Keywords: clinical outcomes; ifx; value; management ... See more keywords
OP61 Cost-Utility Analyses Of Biologics For Refractory Ulcerative Colitis
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Technology Assessment in Health Care"
DOI: 10.1017/s0266462317001465
Abstract: INTRODUCTION: Although many biologics (Bs) have been approved for the treatment of moderate-to-severe Ulcerative Colitis (UC) in patients who have responded inadequately to conventional therapy, the selection of Bs is controversial due to the lack… read more here.
Keywords: ifx; treatment; percent; cost ... See more keywords
Monocytes from infliximab-resistant patients with Crohn’s disease exhibit a disordered cytokine profile
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-68993-1
Abstract: Crohn's disease (CD) is a chronic inflammatory disorder characterized by immune response dysregulation. Tumor necrosis factor-α (TNFα) is a key cytokine in the pathogenesis of CD, as indicated by the efficacy of anti-TNF-α therapy with… read more here.
Keywords: ifx; cytokine profile; non responders; crohn disease ... See more keywords
P295 Comparative Assessment of Infliximab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel Disease
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.419
Abstract: Infliximab (IFX) is a monoclonal antibody that targets cytokine tumor necrosis factor; it is used for the treatment of patients with active inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). IFX… read more here.
Keywords: care; inflammatory bowel; trough levels; ifx ... See more keywords
P384 Therapeutic drug monitoring: performance of the first lateral flow-based Point of Care test for the quantification of infliximab in a finger prick
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.508
Abstract: Promonitor Quick IFX is a lateral flow test (LFT) for the quantification of infliximab (IFX) in human whole blood (finger prick or venous) or serum in 20 minutes. This LFT is based on a sandwich… read more here.
Keywords: performance; test; finger prick; ifx ... See more keywords
Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease.
Sign Up to like & getrecommendations! Published in 2019 at "Inflammatory bowel diseases"
DOI: 10.1093/ibd/izz143
Abstract: BACKGROUND Many pediatric patients with inflammatory bowel disease (IBD) lose response to infliximab (IFX) within the first year, and achieving a minimal target IFX trough concentration is associated with higher remission rates and longer durability.… read more here.
Keywords: inflammatory bowel; ifx; drug; model ... See more keywords
Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomised phase III trial.
Sign Up to like & getrecommendations! Published in 2022 at "Rheumatology"
DOI: 10.1093/rheumatology/keac689
Abstract: OBJECTIVES The primary end point of the pivotal phase III study of infliximab (IFX) s.c. demonstrated non-inferiority of s.c. to i.v. IFX, based on 28-joint DAS-CRP (DAS28-CRP) improvement at Week (W) 22 (NCT03147248). This post-hoc… read more here.
Keywords: efficacy; ifx; post hoc; hoc analysis ... See more keywords
O-005 Combination Therapy with Methotrexate Does Not Change Infliximab Pharmacokinetics in Children with Inflammatory Bowel Disease
Sign Up to like & getrecommendations! Published in 2017 at "Inflammatory Bowel Diseases"
DOI: 10.1097/01.mib.0000512515.46092.5c
Abstract: Background: There remains a question of equipoise regarding the use of anti-TNF-&agr; agent (e.g., infliximab) monotherapy versus combination therapy with immunomodulators (e.g., methotrexate), for the treatment of pediatric Inflammatory Bowel Disease (IBD). The aim of… read more here.
Keywords: ifx; mtx; therapy; combination therapy ... See more keywords
Rapid Infliximab Biosimilar Infusion in Children with Inflammatory Bowel Disease.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of pediatric gastroenterology and nutrition"
DOI: 10.1097/mpg.0000000000003402
Abstract: OBJECTIVES Compare prevalence of infusion reaction (IR) between infliximab (IFX) and infliximab biosimilar (IFX-abda) at standard and rapid rates and measure the impact on health care cost in children with inflammatory bowel disease. METHODS Records… read more here.
Keywords: inflammatory bowel; infusion; ifx abda; children inflammatory ... See more keywords
SAT0046 TNF antagonist drug safety assessment by pharmacovigilance signaling and post-marketing adverse event reports
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.5884
Abstract: Background TNF antagonists have been equally effective in the treatment of immunoinflammatory diseases. However, differences in their characteristics and the introduction of biosimilars may be associated with different safety profiles. Objectives The main goal of… read more here.
Keywords: ifx; safety; database; adverse events ... See more keywords
FRI0194 Use of gloresponsetm NF-κB-RE-LUC2P HEK293 cells to monitor drug and anti-drug antibody levels in serum
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.6352
Abstract: Background Rheumatoid Arthritis (RA) is often treated with anti-TNFα such as infliximab (Ifx) which in a long-term treatment can lead to the development of anti-Ifx antibodies (ATI), resulting in an interference with the drug activity.… read more here.
Keywords: ifx; antibody; serum ifx; drug ... See more keywords